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Ischemia-reperfusion injury is an important cause of liver damage
occurring during surgical procedures including hepatic resection
and liver transplantation, and represents themainunderlying cause
of graft dysfunction post-transplantation. Cellular and biochemical
processes occurring during hepatic ischemia-reperfusion are
diverse and complex, and include the deregulation of the healthy
phenotype of all liver cellular components. Nevertheless, a signiﬁ-
cant part of these processes are still unknown or unclear. The pres-
ent review aims at summarizing the current knowledge in liver
ischemia-reperfusion, but speciﬁcally focusing on liver cell pheno-
type and paracrine interaction deregulations. Moreover, the most
updated therapeutic strategies including pharmacological, genetic
and surgical interventions, as well as some of the scientiﬁc contro-
versies in the ﬁeldwill be described. Finally, the importance of con-
sidering the subclinical situation of liver grafts when translating
basic knowledge to the bedside is discussed.
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whereby cellular damage due to hypoxia and lack of biomechan-
ical stimulus is accentuated upon restoration of oxygen delivery
and shear stress. The signaling events contributing to local hepa-
tocellular damage are diverse and complex, and involve the inter-
action between hepatocytes, liver sinusoidal endothelial cells
(LSEC), Kupffer cells (KC), hepatic stellate cells (HSC), as well as
inﬁltrating neutrophils, macrophages, and platelets [1–4]. It is
important to note that I/R injury represents the main reason of
liver graft dysfunction post-transplantation, independently of
liver basal characteristics, being even more relevant when using
organs from extended-criteria donors.
Hepatocytes are very much negatively affected by I/R, espe-
cially when ischemia is normothermic. Most early changes in
the anoxic hepatocytes occur in the mitochondria. The lack of
O2, as a terminal electron carrier for the mitochondrial respira-
tory chain, immediately interrupts the electron ﬂow causing
the respiratory chain to become reduced. Since mitochondria
are no longer accepting electrons from substrates, a reduction
in pyridine nucleotides occurs, resulting in an increase in the
intracellular NADH/NAD+ ratio. The abruption of oxidative phos-
phorylation rapidly leads to cellular ATP depletion, acceleration
of glycolysis, increased formation of lactate, and alterations on
H+, Na+, and Ca2+ homeostasis, altogether inducing serious dele-
terious effects on the hepatocyte. Ischemia also leads to a consid-
erable increase in cAMP, which is an important factor in glucose
metabolism. cAMP, through the action of cAMP-dependent pro-
tein kinase, leads to the phosphorylation/deregulation of key
enzymes involved in the control of carbohydrate metabolism
[5,6]. Reperfusion injury mainly derives from toxic reactive oxy-
gen species (ROS) generated upon reintroduction of O2 to ische-
mic tissues. ROS are produced from both intracellular and
extracellular sources, being the mitochondria their major source
in liver cells [7] (Fig. 1).
Liver sinusoidal endothelial cells (LSEC) form the vascular wall
of the hepatic sinusoid, lack an organized basal membrane, and
the cytoplasm of these ﬂattened cells is penetrated by open fene-
strations that form clusters called sieve plates, making the hepa-
tic microvascular endothelium discontinuous [8]. LSEC play
important protective roles controlling vascular homeostasis,
inﬂammation, vascular tone, and toxicants clearance. Thus,
maintenance of a healthy LSEC phenotype is indispensable to
minimize any type of liver injury.13 vol. 59 j 1094–1106
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Fig. 1. Hepatocyte phenotype deregulations due to ischemia and reperfusion injury. A summary of the molecular mechanisms affecting the hepatocyte is given, the
speciﬁc modiﬁcations due to I/R are indicated in red. AC, adenine cyclase; AMPK, 50 adenosine monophosphate-activated kinase; ADP, adenine diphosphate; ATP, adenine
triphosphate; A2aR, A2A adenosine receptor; Ang, angiotensin; cAMP, 30-50-cyclic adenosine monophosphate; ER, endoplasmic reticulum; FBPase-1, fructose 1,6-
bisphosphatase; GK, glucokinase; GSH, gluthatione; HO-1, heme oxygenase-1; HSPs, heat shock proteins; MAPK, mitogen-activated protein kinase; NO, nitric oxide; Nrf2,
nuclear factor (erythroid-derived 2)-like 2; O2, superoxide; OAA, oxaloacetic acid; ONOO, peroxynitrite; PEP, phosphoenolpyruvate; PFK, phosphofructokinase; PK,
protein kinase; RBP4, retinol-binding protein 4; SOD, superoxide dismutase; UPR, unfolded protein response; X/XOD, xanthine/xanthine oxidase.
JOURNAL OF HEPATOLOGYLSEC are particularly vulnerable to I/R injury and develop seri-
ous alterations during cold storage (Fig. 2). In fact, pioneering
studies by Caldwell-Kenkel and colleagues described the deregu-
lation of LSEC viability due to I/R injury as plasma membranes
discontinuation, nuclear membranes vacuolization, and cell
shape rounding [9]. These very initial observations, which were
usually reported at the Kupffer Cell Foundation meetings (cur-
rently the International Society for Hepatic Sinusoidal Research),
have been extended during the last decades. Nowadays, it is
accepted that hepatic endothelium damage occurring during cold
preservation represents the initial factor leading to hepatic I/R
injury, determining poor graft microcirculation, platelet activa-
tion, persistent vasoconstriction, upregulation of adhesion mole-
cules, oxidative stress, Kupffer cell activation, neutrophil
inﬁltration, and hepatocyte death.
During the ischemic period, the lack of energetic substrate
interferes with active transmembrane transport, producing
edema in KC and LSEC [10]. This fact, together with the imbalance
between low nitric oxide (NO) bioavailability and exacerbated
endothelin (ET) and thromboxane A2 (TXA2) production, contrib-
utes to narrowing the sinusoidal lumen, and thus to microcircu-
latory dysfunction. Diminished NO levels within the liver during
I/R are derived from both decreased production and increased
scavenging by elevated levels of ROS, and ultimately modulate
the intensity of the I/R injury by regulating neutrophil adhesion,
platelet aggregation, and HSC contraction [11–13]. In addition,
recent studies have demonstrated that lack of biomechanical
stimuli occurring during cold preservation for transplantation
markedly deteriorates LSEC protective phenotype by downregu-
lating the expression of the transcription factor Kruppel-like Fac-
tor 2 (KLF2), which orchestrates the transcription of a variety ofJournal of Hepatology 2013protective genes including the endothelial synthase of NO
(eNOS), the anti-thrombotic molecule thrombomodulin, or the
antioxidant transcription factor Nrf2 [4,14].
Concomitantly to LSEC deregulation, KC suffer from a profound
activation process that is promoted by neighbour hepatic cells-
released damage-associated molecular patterns (DAMPs) and,
under conditionsof sepsisor endotoxemia, alsobypathogen-associ-
atedmolecular patterns (PAMPs) [15,16]. Activated KC signiﬁcantly
increase their release of ROS and pro-inﬂammatory cytokines,
including tumour necrosis factor-a (TNF-a), interleukin-1 (IL-1),
interferon-c (INF-c) and interleukin-12 (IL-12) (Fig. 2) [17,18]. Both
TNF-a and IL-1 upregulate Mac-1 (CD11b/CD18) adhesion proteins
onneutrophils and induce IL-8 synthesis, further promoting neutro-
phil chemotaxiswithin the parenchyma [19].Moreover, IL-1has the
potential to stimulate the release of ROS by neutrophils, which will
further increase TNF-a synthesis by KC [20]. TNF-a stimulates the
expression of the intracellular adhesion molecule-1 (ICAM-1) on
the intraluminal side of LSEC, contributing to neutrophil rolling,
binding, and parenchymal extravasation [20]. TNF-a also induces
P-selectin expression in LSEC, being essential for the recruitment
of neutrophils [21]. TNF-a has been shown to increase the release
of other molecules, including interleukin-6 (IL-6), macrophage
inﬂammatory protein-2 (MIP-2), epithelial neutrophil activating
protein-78 (ENA-78), cytokine-induced neutrophil chemoattrac-
tant-1 (CINC), and a number of CXC motif chemokines (including
CXL-1, -2, and -3). In addition, IL-1 and TNF-a recruit and activate
CD4+ T-lymphocytes, which produce granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), interferon gamma (INF-c) and
tumour necrosis factor beta (TNF-b). These cytokines amplify KC
activation and promote neutrophil recruitment and adherence into
the liver sinusoids [1,22,23].vol. 59 j 1094–1106 1095
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Fig. 2. Liver endothelial deregulations and sinusoidal cellular interactions during ischemia and reperfusion injury. A summary of the molecular mechanisms affecting
the liver sinusoidal cells is shown, the speciﬁc alterations due to I/R are indicated in red. CAM, cell adhesion molecule; cGMP, cyclic guanilate monophosphate; eNOS,
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kinase; TM, thrombomodulin; vWF, von Willebrand factor.
ReviewPlatelets alsoplay an important role inhepatic I/R injury. In fact,
in response to I/R, platelets synthesize and release several factors
that intervene in liver transplant and hepatic regeneration [24].
These include platelet activating factor, cytokines, growth factors
includingNO, TGF-b, serotonin, and calpain. Platelet activating fac-
tor,whichcanalsobeproducedbyKCandLSEC, primesneutrophils
for ROS generation and leukotriene B4 release, further contributing
to the ampliﬁcation of the neutrophil response [3]. Platelets also
adhere to the hepatic sinusoids and induce programmed LSEC
death through the production of NO, which ultimately will result
in the potent toxicant peroxynitrite (Fig. 2) [1,25].
Controversial mechanisms of liver cells deregulation in
hepatic I/R injury
Although most of published data converge on the currently
known molecular mechanisms underlying liver cells deregulation
during I/R injury, other ﬁndings are not completely understood or
validated up to now. The following data summarizes some of
these controversies, and may provide a better understanding of
why hepatic I/R injury still remains an unresolved problem in
clinical practice.1096 Journal of Hepatology 2013Sinusoidal endothelial cells
Although LSEC injury due to I/R was reported in the late 1980s
[9], this cell type has somehow been relegated to a secondary
place and only few research groups have devoted their efforts
to better understand the pathophysiology of LSEC during I/R.
Rauen and colleagues did demonstrate that LSEC under cold
ischemia and warm reperfusion conditions exhibit markedly
increased levels of ROS that ultimately lead to decrease in LSEC
viability [26]. Other studies demonstrated upregulation of
adhesion molecules [27], actin disassembly and cell deregula-
tion due to an increment in calcium-derived calpain activity
[28], and LSEC death due to elastase-mediated paracrine inter-
actions with leucocytes [29]. Nevertheless, scarce reports inves-
tigated the physiological consequences of SEC deregulation on
hepatic I/R injury, and more importantly, very little is currently
known about the relative importance of LSEC de-regulation due
to I/R on the global reduction in organ viability and function
post-transplantation. In fact, very recent data obtained in
experimental models of liver preservation for transplantation
demonstrated that cold storage per se negatively affects the
LSEC phenotype, becoming pro-inﬂammatory, pro-thrombotic,vol. 59 j 1094–1106
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and vasoconstrictor, which is translated into acute endothelial
dysfunction development [14]. Importantly, the alterations in
LSEC phenotype occur due to the abolition of the blood-derived
biomechanical stimuli, which have been demonstrated to be
protective, and suggest that part of the beneﬁcial effects of
the normothermic machine perfusion may derive from the con-
tinuous vascular stimulation obtained with this novel and
promising strategy [30–32].
Kupffer cells
It has been shown that KC, isolated after in vivo I/R, spontane-
ously release increased amounts of TNF-a compared to controls,
thus proposing them as main generators of this pro-inﬂammatory
cytokine during liver I/R [33]. However, other studies have con-
tradicted this hypothesis demonstrating that inactivation of KC
with gadolinium chloride before rat liver transplantation does
not reduce expression of TNF-a, then suggesting that KC are
not the only source of TNF-a in the liver [34]. Of note, the stim-
ulatory state of KC after I/R depends on the duration of ischemia,
and may also differ between ischemia at 4 C and that at 37 C,
and between liver grafts types, which altogether probably leads
to different mechanisms of liver damage [23].
Neutrophil accumulation
As described above, activation of neutrophils has been impli-
cated in the hepatic microvascular dysfunction and parenchy-
mal damage associated with I/R [35]. Still, a controversial
topic is the question of how neutrophils actually accumulate
within the liver. The classical theory argues that the increased
expression of adhesion molecules, such as ICAM-1 and P-selec-
tin, plays a key role in neutrophil collection and the subsequent
liver damage associated with I/R [35]. By contrast, it has also
been reported that neutrophil accumulation in the liver after
I/R occurs independently of the upregulation of either ICAM-1
or P-selectin [36]. This alternative theory proposed that
mechanical factors such as active vasoconstriction, vascular cell
swelling and injury, and reduced membrane ﬂexibility after
activation of neutrophils are involved in trapping these
leukocytes into the sinusoids [37]. Indeed, the extensive vascu-
lar injury happening during reperfusion partly eliminates the
LSEC barrier, thus the neutrophils have direct access to hepato-
cytes [3]. According to this alternative hypothesis, anti-ICAM-1
therapies failed to protect liver grafts against I/R injury [38].
Regarding the possible role of P-selectin in neutrophil recruit-
ment, although LSEC neither contain Weibel Palade bodies nor
transcriptionally upregulate relevant levels of P-selectin after
liver injury [39], a variety of interventions directed against
selectins in the experimental scenario of liver I/R injury reduced
hepatic neutrophil accumulation and hepatocellular injury [40].
Since these ﬁndings cannot be explained by the prevention of
P-selectin-dependent rolling over the hepatic sinusoids, it has
been suggested that most models of liver I/R may include some
degree of intestinal ischemia, which would lead to neutrophil
accumulation in remote organs including the liver [23,41]. Thus,
the lower amount of neutrophils in the liver when selectins
are blocked may be a secondary effect derived from the protec-
tion of anti-selectin therapy against intestinal reperfusion
injury [41].Journal of Hepatology 2013Time-dependent sensitivity of hepatocyte and LSEC to
ischemia
Two of the liver cell types mostly affected during I/R injury are
hepatocytes and sinusoidal endothelial cells, however, they show
differential sensitivity to different types of ischemia: hepatocytes
are more sensitive to warm ischemia, and LSEC to cold ischemia
[17,42]. In fact, although most hepatocytes remain viable for 48 h
after cold preservation and warm reperfusion, LSEC rapidly suffer
from severe damage (up to 50% of them end up as non-viable
cells) [43].
The severity of hepatocyte damage depends on the length of
warm ischemia. Short periods of ischemia (60 min) result in
reversible cell injury in which liver oxygen consumption returns
to normal levels when oxygen is resupplied during reperfusion.
Nevertheless, reperfusion after more prolonged periods of warm
ischemia (120–180 min) results in irreversible cell damage, being
90 min of warm ischemia the estimated time limit for hepato-
cytes survival [44]. In cold ischemia, in vitro studies demon-
strated maintenance of hepatocyte function and viability up to
72 h of preservation [45], however, experimental models of liver
transplantation indicate that 24 h, or even shorter periods, of cold
ischemia may be accompanied by the development of graft pri-
mary non-function after transplantation [46]. The divergence
between in vitro and in vivo studies is attributed to the signiﬁcant
sinusoidal damage occurring during cold storage, which will
result in microcirculatory abnormalities and hepatocyte injury.
In fact, in vitro experiments demonstrated that LSEC function
and viability are signiﬁcantly compromised after 8–16 h of cold
storage, and completely blunted afterwards [47,48]. Moreover,
studies using experimental models of liver preservation for trans-
plantation showed acute endothelial dysfunction development
after 16 h of cold storage, associated with signiﬁcant hepatocellu-
lar injury and death [14]. Considering the intimate cellular cross-
talk between LSEC and hepatocytes, it is very possible that LSEC
injury due to cold storage may negatively affect hepatocyte via-
bility, and vice versa. In fact, hepatocytes from cold stored livers
exhibit perturbations in key hepatocellular functions like solute
transport or drug metabolism, together with low levels of ade-
nine nucleotides that may trigger proteolytic events, altogether
contributing to liver graft dysfunction [49]. These observations
indicate that aside from reducing LSEC damage, I/R injury therapy
may also beneﬁt from strategies aimed at maintaining appropri-
ate hepatocyte functions [49,50].
Another factor affecting the time-dependent sensitivity of
liver cells to I/R is the percentage of ischemia applied. The extent
of hepatic injury, as well as part of the underlying mechanisms,
depends on whether a total or partial hepatic ischemia is con-
ducted [51,52]. Different authors have suggested that this fact
could be explained by the ‘‘stealing phenomenon’’: In contrast
to what happens in the 100% hepatic ischemia, during ischemia
of the left and median lobes (70% of ischemia), the hepatic ﬂow
is totally shunted through the right lobes, and even after the
release of the occlusion, a signiﬁcant amount of ﬂow is still
deﬂected (‘‘steeled’’) through the right lobes, until vascular resis-
tance of the post-ischemic lobes decreases. This is due to the
physical fact that blood will ﬂow through the vascular path with
less resistance. Thus, the recovery of blood ﬂow and hepatic
perfusion in the post-ischemic lobes occurs much later in the case
of partial than total hepatic ischemia [53]. In line with thesevol. 59 j 1094–1106 1097
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observations, the beneﬁts of some drugs such as ATP–MgCl2
depend on the extent of the hepatic ischemia used.Type of cell death occurring in hepatocytes and LSEC subjected
to ischemia
The exact mechanism of cell death in hepatic I/R injury remains
unclear. Apoptosis of hepatic cells, including hepatocytes and
LSEC, due to I/R has been described by different reports [54,55],
and partly occurs through the c-Jun N-terminal kinase 2-medi-
ated mitochondrial permeability transition pathway that ulti-
mately leads to cytochrome C release and caspase activation
[56,57]. On the other hand, other groups oppose the view that
the majority of cells undergo apoptosis in response to either
warm or cold I/R injury, believing that necrosis is the main form
of cell death [58]. This last hypothesis derives from the idea that
the proportion of cells undergoing apoptosis described in other
studies is not of signiﬁcant magnitude, and that the degree of cas-
pase activation does not correlate with the number of LSEC and
hepatocytes supposedly undergoing apoptosis. Thus, a contro-
versy has emerged over the past years as to whether necrotic
or apoptotic cell death accounts for the severe parenchymal
injury observed during hepatic reperfusion. Remarkably, and
although it has been assumed that necrosis and apoptosis are dif-
ferent processes, a new term ‘‘necrapoptosis’’ has been coined to
describe a process that begins with a common death signal and
culminates in either cell lysis (necrotic cell death) or pro-
grammed cellular resorption (apoptosis), depending on factors
such as the decline of cellular ATP levels [59].Relevance of the type of liver undergoing I/R
A variety of subclinical factors including starvation, donor age,
and graft steatosis contribute to enhance liver susceptibility to
I/R injury, thus increasing patient risks. It is well-known that
the shortage of organs has led care centres to expand their crite-
ria for the acceptance of graft donors. Some of these criteria
include the use of organs from elderly donors and steatotic liver
grafts [60–62]. However, donor age higher than 70 years, as well
as use of grafts with moderate steatosis, is associated with lower
patient and graft survival [63,64]. Moreover, hepatic steatosis is
the current major cause of graft rejection for liver transplanta-
tion, exacerbating organ shortage problem [1,23,58]. Therefore,
minimizing the adverse effects of I/R injury especially in grafts
from extended-criteria donors would increase the number of
both suitable grafts and patients who successfully recover from
a liver transplant. The ﬁrst step towards achieving this objective
is a full understanding of the mechanisms involved in I/R injury
in these suboptimal organs.
Starvation
In clinical liver transplant, starvation of the donor due to pro-
longed intensive care unit hospitalization or to the lack of
adequate nutritional support increases the incidence of hepato-
cellular injury and primary non-function [65]. The pre-existent
nutritional status is a major determinant of hepatocyte injury
associated with I/R. Based on the nutritional status, several
experimental and clinical studies support the hypothesis that
the availability of glycolytic substrates is important for1098 Journal of Hepatology 2013maintenance of hepatic ATP levels during ischemia and for a
functional recovery during reperfusion [37,66]. Fasting exacer-
bates I/R injury because the low pool of glycogen results in more
rapid ATP depletion during ischemia [66]. In addition, fasting
causes alterations in tissue antioxidant defences, accelerates the
conversion of xanthine dehydrogenase to xanthine oxidase dur-
ing hypoxia, and induces mitochondrial alterations [65]. Consid-
ering these observations, an artiﬁcial nutritional support may
represent a new approach for the prevention of reperfusion injury
in fasted patients [67]. However, fasting has been reported to
improve organ viability and survival when long periods of ische-
mia are applied, as it reduces KC phagocytosis and the generation
of TNF-a [68]. To understand these apparently contradictory
results, it is important to consider the different experimental con-
ditions of those investigations. A beneﬁcial effect of high glyco-
gen content is mainly expected under conditions of short
ischemia, when high metabolic reserves within the liver may
attenuate ischemic cell injury and preserve defence functions
against cytotoxic mediators of KC. Conversely, long ischemic peri-
ods may preferentially demand lower metabolic reserves since
KC become de-activated and will not contribute to early graft
injury.
Age
Under warm hepatic ischemia, mature adult mice showmarkedly
increased neutrophil activity and intracellular ROS, and
decreased mitochondrial function compared with young adult
mice. Mature adult mice have much lower hepatic expression
of the cytoprotective heat shock protein 70 (HSP70) than young
adult mice. In contrast, serum HSP70 levels, which have been
linked to subsequent tissue injury, are higher in mature than in
young adult mice [69]. These alterations may contribute to the
exacerbated liver injury after I/R observed in elderly mice com-
pared with young animals. On the other hand, using the experi-
mental model of the isolated perfused liver, previous studies
demonstrated lower production of oxyradicals in old animals
compared to livers from young rats. This fact was explained by
lower KC activity, reduction in liver blood ﬂow, and the impaired
functions and structural alterations observed in the livers of old
rats [70]. In hepatocytes from mature adult mice, delayed activa-
tion of nuclear factor kappa B (NFjB) in response to TNF-a and
virtually no production of macrophage inﬂammatory protein 2
have been detected [69]. Evidently, further investigations are
required to better understand the pathophysiological status of
liver grafts from old donors.
Steatosis
The ﬁrst step to minimize the adverse effects of I/R in steatotic
livers is a full understanding of the mechanisms involved in I/R
injury in these marginal organs. Microcirculatory dysfunction
probably represents the main underlying mechanism of steatotic
liver I/R injury [67,71,72], nevertheless, other hypotheses have
also been suggested. Hepatocyte damage is remarkably higher
in steatotic livers than in non-steatotic livers [73], and may con-
tribute to their poor tolerance to I/R. Hepatocyte de-regulation
has several causes, it may be partially explained due to an
increased sensitivity to ROS that will affect mitochondrial pro-
cesses including those responsible for ATP synthesis. In fact, stea-
totic livers synthesise less ATP than non-steatotic livers duringvol. 59 j 1094–1106
Table 1. Pharmacological strategies to protect livers against ischemia/reperfusion injury.
Pharmacological therapy
Drug Species Experimental model Ischemic 
time
Effect
A-779 [79]
(Ang-(1-7) receptor 
antagonist)
Rat Cold ischemia 6 h ↓ Hepatic injury, oxidative stress and necrosis
↑ Survival
ABC294640 [87]
(inhibitor of sphingosine 
kinase-2) 
Mice Warm ischemia 1 h ↓ Hepatic injury, neutrophil infiltration, NO synthase, NF-kB 
and TNFα,
↑ Survival
Allopurinol [88]
(XOD inhibitor)
Mice Warm ischemia 30 min ↓ Oxidative stress and XOD activity
AT1R, AT2R II [89]
(Ang II type I and II receptor 
antagonist)
Rat Warm ischemia + 
hepatectomy
60 min ↓ Hepatic injury, MDA and nitrotirosines
Apocynin [88]
(NADPH oxidase inhibitor)
Mice Warm ischemia 30 min ↓ Oxidative stress and NADPH oxidase activity
Ascorbate [90]
(Vitamin C or L-ascorbic acid)
Rat Warm ischemia 30 min ↓ Hepatic injury and apoptotic kupffer cells 
Atorvastatin [91]
(HMG-CoA reductase 
inhibitor, vasoprotector)
Mice Warm ischemia 60-90 
min
↓ Hepatic injury, and oxidative stress
Atorvastatin [92] (HMG-
CoA reductase inhibitor, 
vasoprotector)
Mice Warm ischemia 60 min ↓ Hepatic injury
↑ TLR4 and NF-kB activation
bpV (HOpic) [93]
(PTEN inhibitors)
Rat Warm ischemia 60 min ↓ Hepatic injury, apoptosis and PTEN
↑ PBK/Akt activation
Captopril [94]
(Ang II blockers) 
Rat Warm ischemia 60 min ↓ Hepatic injury
Cardiotrophin-1 [95]
(cytokine)
Pig Cold ischemia 4 h ↓ Hepatic injury, oxidative stress, IL-1β, TNFα, IL-6 and 
caspase-3
↑ Survival
CORM-2 [96]
(carbon monoxide-releasing 
molecule-2)
Rat Warm ischemia 60 min ↓ Hepatic injury, neutrophils, apoptosis, NF-kB, TNF, IL-6, 
and ICAM expression
EGF [97]
(epidermal growth factor)
Rat Warm ischemia 60 min ↓ Hepatic injury
Erythropoietin [98]
(glycoprotein hormone)
Mice Cold ischemia 90 min Hepatocyte and SEC protection
↓ Hepatic injury and apoptosis
17β-Estradiol [99]
(steroid hormone)
Rat Cold ischemia 4 h ↓ Hepatic injury, apoptosis, and glycogen synthase 
kinase-3β
↑ Survival and AKT
Fasudil [100]
(Rho-kinase inhibitor) 
Rat Warm ischemia 30 min ↓ Hepatic injury, HSC activation, endothelin 1 and portal 
perfusion pressure
↑ Survival
FK506 [101] 
(immunosupressant)
Rat Cold ischemia
Warm ischemia
60 min
60 min
↓ Hepatic injury, edema, necrosis and AIF-1 activation
Fructose [102]
(monosaccharide)
Rat Cold ischemia 26 h Hepatocyte and LSEC protection
↓ Hepatic injury
↑ ATP
GW9662 [80]
(PPARγ antagonist)
Rat Cold ischemia 6 h ↓ Hepatic injury 
IGF-1 [97]
(insulin-like growth factor)
Rat Warm ischemia 60 min ↓ Hepatic injury
MF-1 [103]
(metron factor-1)
Rat Warm ischemia 90 min ↓ Hepatic injury and oxidative stress
↑ Survival and NO synthesis
MPLA [104]
(TLR4 agonist)
Rat Cold ischemia 6 h ↓ Hepatic injury
↑ Survival
n-3 PUFA [105]
(polyunsaturated fatty acid)
Rat Warm ischemia 60 min ↓ Hepatic injury, inflammation and oxidative stress
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Pharmacology therapy
Drug Specie Experimental model Ischemic 
time
Effect
Nilotinib [106]
(tyrosine kinase inhibitor)
Mice Warm ischemia 1 h ↓ Hepatic injury, apoptosis, IL-1β, IL-6, MCP-1, MIP-2, 
JNK, p38 MAPK, activation and recruitment of inflammatory 
monocytes 
PD123319 [94]
(Ang II blockers) 
Rat Warm ischemia 60 min ↓ Hepatic injury
PNU-282987 [107]
(α7 nicotinic acetylcholine 
receptor agonist) 
Mice Warm ischemia 60 min ↓ Hepatic injury, NF-kB activation and HMGB1 expression 
RBP4 [80]
(adipocytokine)
Rat Cold ischemia 6 h ↓ Hepatic injury and PPARγ expression 
Retinol [108]
(vitamin A)
Rat Warm ischemia 60 min ↓ Hepatic injury and steatosis
↑ Regeneration
rHuEPo [109]
(glycoprotein hormone)
Rat Cold ischemia 6 h ↓ Hepatic injury and apoptosis
↑ Survival
RMT1-10 [110]
(TIM-1 blocker) 
Mice Cold ischemia 20 h ↓ Hepatic injury, neutrophil infiltration and NF-kB activation
rMnSOD [111]
(Antioxidant)
Rat Cold ischemia 16h Hepatocyte and LSEC protection
↓ Hepatic injury and inflammation
Improvement in hepatic microcirculation and endothelial 
dysfunction in healthy and steatotic grafts.
rPSGL-Ig [112]
(selectin antagonist) 
Human Cold ischemia 60 min ↓ Hepatic injury
↑ IL-10
Sevofluorane [113]
(anesthesic inhalation agent)
Human Warm ischemia 30 min ↓ Hepatic injury and postoperative complications
Simvastatin [71]
(HMG-CoA reductase 
inhibitor, vasoprotector)
Rat Cold ischemia 16 h Hepatocyte and LSEC protection in mild and severe 
steatosis
↓ Hepatic injury, apoptosis and inflammation
Improvement in hepatic microcirculation and endothelial 
dysfunction
Sirolimus [114] 
(immunossupressant)
Rat Warm ischemia + 
hepatectomy
60 min ↓ Hepatic injury, apoptosis, neutrophil infiltration and MDA
SQ22536 [115]
(adenylate cyclase inhibitor)
Rat Cold ischemia 6 h ↓ Hepatic injury, lactate accumulation, oxidative stress and 
microvascular disorders
↑ Survival
Tauroursodeoxycholate [78, 
104]
(bile acid)
Rat Cold ischemia
Warm ischemia + 
hepatectomy
6 h
60 min
↓ Hepatic injury and PPARγ expression 
↓ Endoplasmic reticulum stress
TBC-1269 [116]
(PAN-selectin antagonist)
Mice Warm ischemia 90 min ↓ TNFα and ERK 1/2 expression
↑ IL-10
Trans-resveratrol [117] 
(antioxidant)
Rat Warm ischemia 60 min ↓ Hepatic injury and MDA
 ↑ Catalase, GSH and SOD
Tetrandine [118]
(calcium channel blocker)
Mice Warm ischemia 90 min ↓ Hepatic injury, neutrophil accumulation and MDA
 ↑ SOD
WY-14643 [81]
(PPAR-α agonist) 
Rat Warm ischemia 60 min ↓ Hepatic injury, inflammatory cytokines and oxidative stress
WY-14643 [119]
(PPAR-α agonist) 
Rat Warm ischemia 90 min ↓ Hepatic injury
WY-14643 [120]
(PPAR-α agonist) 
Mice Warm ischemia 90 min ↓ Hepatic injury
YM-53601 [91]
(squalene synthase inhibitor)
Mice Warm ischemia 60-90 
min
↓ Hepatic injury, oxidative stress and steatosis
AIF-1, allograft inﬂammatory factor 1; GSH, glutathione; HMGB1, high mobility group box 1; HSC, hepatic stellate cells; IL, interleukin; JNK, jun N-terminal kinase; MCP-1,
monocyte chemoattractant protein-1; MDA, malondialdehyde; MIP-2, macrophage inﬂammatory protein-2; MPO, myeloperosidase; NADPH, nicotinamide adenine
dinucleotide phosphate; NF-kB, nuclear factor kappa B, NO, nitric oxide; PPAR, peroxisome proliferator-activated receptor; PTEN, phosphatidylinositol-3,4,5-trisphosphate
3-phosphatase; LSEC, liver sinusoidal endothelial cells; SOD, superoxide dismutase; TLR4, toll-like receptor 4; TNF, tumor necrosis factor; XOD, xanthine oxidase.
Table 1 (continued).
Reviewpost-ischemic reperfusion [7,74], being the upregulation of the
mitochondrial uncoupling protein 2 a key underlying mechanism
[75]. In addition, it has been described that hepatocytes with1100 Journal of Hepatology 2013fatty inﬁltration develop massive necrosis after I/R injury, instead
of apoptosis observed in non-steatotic livers [61]. This fact may
be due to low ATP production and dysfunction of regulators ofvol. 59 j 1094–1106
Table 2. Additives for preservation solutions to protect livers against ischemia/reperfusion injury.
Additives for preservation solution
Drug or additive Species Experimental model Ischemic 
time
Effect
APC [121]
(anticoagulant serine 
protease)
Rat Cold ischemia 2, 6, 20 h ↓ Hepatic injury, apoptosis, hyaluronic acid, IL-6, TNFα, 
endothelin-1, infiltration of neutrophils and macrophages
 ↑ Survival and hepatic microcirculation
Carvedilol [122]
(β-blocker and antioxidant)
Rat Cold ischemia 24 h ↓ Hepatic injury, microcirculatory diseases, ATP depletion, 
oxidative stress and mitochondrial damage 
EGF, IGF-1 [123]
(growth factors)
Rat Cold ischemia 24 h ↓ Hepatic injury and necrosis
Oxycyte [124] 
(perfluorocarbon)
Rat Cold ischemia 8 h ↓ Hepatic injury
Peg-Alb [125]
(polyethylen glycol-albumin)
Rat Cold ischemia 30 h Hepatocyte and LSEC protection
↓ Hepatic injury
↑ Portal vein inflow
rMnSOD [111]
(Antioxidant)
Rat
Human
Cold ischemia 16h ↓ Hepatic oxidative stress accumulation
RXP409 [126]
(MMP inhibtor)
Rat Cold ischemia 42 h ↓ Hepatic injury
Simvastatin [14]
(HMG-CoA reductase 
inhibitor, vasoprotector)
Rat Cold ischemia 16 h Hepatocyte and LSEC protection
↓ Hepatic injury, apoptosis and inflammation
Improvement in hepatic microcirculation and endothelial 
dysfunction
TAT-HO-1 [127]
(heme oxygenase fusion 
protein )
Rat Cold ischemia 2, 6, 12,
18 h
Hepatocyte and LSEC protection
↓ Hepatic injury and BAX
↑ Bcl2
Tauroursodeoxycholate [128] 
(bile acid)
Rat Cold ischemia 2 h ↓ Endoplasmic reticulum stress
APC, activated protein C; BAX, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; EGF, epidermal growth factor; HO-1, heme oxygenase-1; IGF-1, insulin-like growth
factor 1; IL-6, interleukin-6; MMP, metalloproteinase; NO, nitric oxide; PAF, platelet activating factor; LSEC, liver sinusoidal endothelial cells; TNFa, tumor necrosis factor a.
Table 3. Gene therapy strategies aimed at protecting liver grafts against ischemia/reperfusion injury.
Gene therapy
Target gene/strategy Species Experimental model Ischemic 
time
Effect
Adiponectin [81] (siRNA) Rat Warm ischemia 1 h ↓ Hepatic injury and oxidative stress
Adipose-derived stem cells 
[129]
Mice Warm ischemia + 
hepatectomy
15 min Hepatocyte protection
↓ Hepatic injury
↑ VEGF
Adipose tissue-derived 
mesenchymal stem cells [130] 
Rat Warm ischemia 60 min Hepatocyte protection
↓ Hepatic injury, apoptosis and oxidative stress
FGL2 [131]
(transgenic) 
Mice Warm ischemia 60 min Hepatocyte and LSEC protection
↓ Hepatic injury
NF-kB decoy oligonucleotides 
[132] 
Rat Warm ischemia 60 min ↓ Hepatic injury, NF-kB, IL-6 and TNFα
PHD1 [133]
(knockout)
Mice Warm ischemia 90 min Hepatocyte protection
↓ Hepatic injury and oxidative stress
TLR4 [134]
(knockout)
Mice Warm ischemia 60 min ↓ Hepatic injury, cytokine release and neutrophil infiltration 
TLR4 [135]
(knockout)
Mice Warm ischemia 35 min ↓ Hepatic injury, neutrophil infiltration and pro-inflammatory 
cytokines
FGL2, ﬁbrinogen-like protein 2; IL-6, interleukin-6; NF-kB, nuclear factor kappa B; PHD1, prolyl hydroxylase 1; TLR4, toll-like receptor 4; TNFa, tumor necrosis factor a;
LSEC, liver sinusoidal endothelial cells; VEGF, vascular endothelial growth factor.
JOURNAL OF HEPATOLOGYapoptosis (Bcl-2, Bcl-xL, and Bax), and may explain why caspase
inhibition, a highly protective strategy in non-steatotic livers, had
no effects on hepatocyte injury in steatotic livers [73]. In experi-
mental models of liver transplantation, exogenous NO adminis-Journal of Hepatology 2013tration protected non-steatotic grafts but was ineffective, or
even noxious, in livers with steatosis. The injurious effects of
exogenous NO donors was explained by exaggerated peroxyni-
trite generation caused by ROS overproduction [76]. Hemevol. 59 j 1094–1106 1101
Table 4. Surgical strategies to protect livers against ischemia/reperfusion injury.
Surgical strategy
Strategy Species Experimental model Ischemic 
time
Effects
IP [80] Rat Cold ischemia 6 h ↓ Hepatic injury
IP [136] Rat Warm ischemia 60 min Hepatocyte and LSEC protection
↓ Hepatic injury and LTC4 content
IP [137] Mice 
(cirrhotic)
Warm ischemia 60-75min ↓ Hepatic injury, apoptosis and necrosis
IP [138] Pig Warm ischemia + 
hepatectomy
120 min ↓ Hepatic injury
IP [139] Human Warm ischemia + 
hepatectomy
40-90 
min
↓ Hepatic injury and necrosis
↑ Autophagy 
IP [140] Human Warm ischemia + 
hepatectomy
30-40 
min
↓ Hepatic injury and postoperative complications 
IC [141] Rat (old) Warm ischemia 45 min ↓ Hepatic injury
More effective than IP
IC [137] Mice 
(cirrhotic)
Warm ischemia 15-30 
min
↓ Hepatic injury, apoptosis and necrosis
RP [142] Mice Warm ischemia 60 min ↓ Hepatic injury
MP [31, 32] (normothermic) Pig Cold ischemia 4 h ↓ Hepatic injury and inflammation
↑ Survival
MP [143]
(hypothermic) (4)
Pig Cold ischemia 6-7 h Hepatocyte, LSEC and mitochondrial protection
↓ Kupffer cell activation
MP [144] (sub-normothermic) Rat Cold ischemia 6 h ↓ Hepatic injury and oxidative stress
Portocaval shunt [145] Pig Cold ischemia 5 h Hepatocyte and LSEC protection
↓ Hepatic injury
IC, intermittent clamping; IP, ischemic preconditioning; LTC4, leukotriene C4; MP, Machine perfusion; RP, remote preconditioning; LSEC, liver sinusoidal endothelial cells.
Reviewoxygenase-1 (HO-1) activators such as cobalt (III) protoporphyrin
IX might protect livers against warm I/R injury. However, a much
lower dose of the HO-1 activator is required to protect steatotic
livers, as they show higher HO-1 basal levels than non-steatotic
livers [77]. Steatotic livers also differed from non-steatotic grafts
in their response to the unfolded protein response and endoplas-
mic reticulum stress, indeed the expression of inositol-requiring
enzyme 1 and PKR-like endoplasmic reticulum kinase is lower
in the presence of steatosis [78]. Differences have also been
observed analyzing the role of the renin-angiotensin system,
non-steatotic grafts exhibited higher angiotensin (Ang)-II and
lower Ang-(1–7) levels than steatotic grafts [79]. Moreover,
reduced retinol binding protein 4 and increased peroxisome pro-
liferator-activated receptor gamma (PPAR-c) levels were
observed in steatotic livers compared to non-steatotic livers
[80]. The increased vulnerability of steatotic livers subjected to
I/R has been also associated with increased adiponectin, oxidative
stress and IL-1 levels, and reduced capability to generate IL-10,
PPAR-a and Retinol-Binding Protein 4 [80–82].
Very importantly, it should be considered that the mecha-
nisms involved in hepatic I/R injury may differ depending on
the method used to induce experimental steatosis. In contrast
with other models of steatosis, both dietary and alcohol exposure
induces the production of superoxide dismutase/catalase-insensi-
tive ROS, which may partly justify steatotic liver failure after
transplantation [83]. Neutrophils, which have been involved in
the increased vulnerability of alcohol-induced steatotic livers to
I/R injury, would not account in I/R damage in non-alcoholic stea-
totic livers. Similarly, the role of TNF-a in the vulnerability of stea-1102 Journal of Hepatology 2013totic livers to I/R injury may depend on the type of steatosis
[23,84]. All the aforementioned observations indicate that thera-
pies that are effective in non-steatotic livers may either be useless
in the presence of steatosis, or the effective drug dose may differ
between types of grafts [1,76,77]. On the other hand, some phar-
macological compounds would only be effective in steatotic livers
[23,58]. In summary, the different mechanisms involved in hepa-
tic I/R injury depending on the type of steatosis could explain the
difﬁculties to translate our current knowledge to the bedside.Strategies to prevent hepatic I/R injury
As a consequence of the incipient amount of uncovered molecu-
lar mechanisms responsible for hepatic I/R injury, a variety of
new therapeutic strategies have been developed (Tables 1–4).
Due to limitation in review length, only those strategies reported
during the last 5 years have been included in the present review.
For less recent studies please refer to previous articles
[1,23,58,85,86].
Concluding remarks and future directions
Over the past years, our knowledge about the mechanisms
involved in the development of liver injury due to I/R has signif-
icantly improved, and it has consequently been accompanied by a
long list of potential therapeutic alternatives. However, ischemia-
reperfusion injury still represents a serious problem in the clini-
cal practice probably because very few basic (or translational)vol. 59 j 1094–1106
JOURNAL OF HEPATOLOGY
studies have successfully been applied at the bedside. This impor-
tant drawback in hepatic I/R experimental research may have
several origins.
Firstly, and as stated along this review, it should be consid-
ered that the mechanisms involved in hepatic I/R very much
depend on the experimental conditions used: which type of
research is done (in vitro, ex vivo, in vivo), type of ischemia
applied (warm or cold), period of ischemia (ranging from min-
utes to days), extension of hepatic ischemia (partial or total),
graft subclinical situation (healthy, steatotic, aged. . .), etc. Thus,
new therapeutic strategies from experimental studies should be
considered speciﬁc to the concrete experimental/surgical condi-
tions used, and most probably they cannot automatically be
validated for a different I/R situation. Secondly, although we
certainly know part of the underlying molecular mechanisms
of I/R injury in hepatocytes and Kupffer cells, much fewer
knowledge has been gained for other key hepatic cells such
as liver sinusoidal endothelial cells or hepatic stellate cells.
Thus further investigations are still required. Nevertheless, liver
cells phenotype modiﬁcations due to I/R injury should be
investigated in experimental conditions that maximally mimic
the hepatic sinusoid environment, including the possibility of
paracrine interactions and under physiological biomechanical
stimuli. Third, it should be taken into consideration that the
possible applicability of basic research knowledge is even more
difﬁcult in clinical situations with extended-criteria donors. The
relative homogeneity of liver steatosis obtained in genetically
modiﬁed animals or animals under dietary alterations cannot
be compared to humans, where surgeons are still looking for
a reliable method for hepatic lipid content quantiﬁcation, and
similarly happens with elderly donors, non-beating heart
donors, etc. Overall foster complicating the applicability of
basic research.
In conclusion, multidisciplinary research groups should
devote additional efforts to better understand the cellular altera-
tions and the crosstalk within the liver during I/R injury to
ultimately develop effectual therapeutic strategies aimed at
improving graft viability post-transplantation or resection, and
at signiﬁcantly increasing the organ donor pool.
Key Points
• Hepatic ischemia and reperfusion injury (I/R)
represents the main underlying mechanism for
graft dysfunction, and failure, post-transplantation,
especially in liver grafts from extended-criteria donors
•  I/R significantly affects the phenotype of all hepatic
cells, which broadly become pro-inflammatory,
pro-thrombotic, pro-apoptotic, and vasoconstrictor.
Intrahepatic paracrine cellular interactions occurring
during I/R importantly contribute to global hepatic
dysfunction
• The molecular mechanisms, and therefore the possible
therapeutic strategies, of hepatic I/R tightly depend on
the experimental model of liver I/R utilized, as well as
on the subclinical characteristics of each liver graft.
Translation of basic science to the bedside should
consider the experimental conditions used in the
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